[{"address1": "822 A1A North", "address2": "Suite 306", "city": "Ponte Vedra", "state": "FL", "zip": "32082", "country": "United States", "phone": "904 300 0701", "website": "https://www.cadrenal.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.", "companyOfficers": [{"maxAge": 1, "name": "Mr. Quang X. Pham", "age": 58, "title": "Chairman & CEO", "yearBorn": 1965, "fiscalYear": 2022, "totalPay": 822173, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Douglas W. Losordo FACC, FAHA, M.D.", "age": 65, "title": "Chief Medical Officer", "yearBorn": 1958, "fiscalYear": 2022, "totalPay": 23360, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400, "priceHint": 4, "previousClose": 0.6508, "open": 0.642, "dayLow": 0.58, "dayHigh": 0.6795, "regularMarketPreviousClose": 0.6508, "regularMarketOpen": 0.642, "regularMarketDayLow": 0.58, "regularMarketDayHigh": 0.6795, "forwardPE": -1.4462222, "volume": 93657, "regularMarketVolume": 93657, "averageVolume": 376373, "averageVolume10days": 126540, "averageDailyVolume10Day": 126540, "bid": 0.61, "ask": 0.75, "bidSize": 1800, "askSize": 800, "marketCap": 10418332, "fiftyTwoWeekLow": 0.395, "fiftyTwoWeekHigh": 3.14, "fiftyDayAverage": 0.90326, "twoHundredDayAverage": 0.8792, "currency": "USD", "enterpriseValue": 2037161, "floatShares": 6127242, "sharesOutstanding": 16008500, "sharesShort": 7168, "sharesShortPriorMonth": 196662, "sharesShortPreviousMonthDate": 1706659200, "dateShortInterest": 1709164800, "sharesPercentSharesOut": 0.00059999997, "heldPercentInsiders": 0.5782, "heldPercentInstitutions": 0.04236, "shortRatio": 0.01, "shortPercentOfFloat": 0.0013, "impliedSharesOutstanding": 16008500, "bookValue": 0.591, "priceToBook": 1.1011844, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -8357086, "forwardEps": -0.45, "enterpriseToEbitda": -0.267, "52WeekChange": -0.58000004, "SandP52WeekChange": 0.30583346, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "CVKD", "underlyingSymbol": "CVKD", "shortName": "Cadrenal Therapeutics, Inc.", "longName": "Cadrenal Therapeutics, Inc.", "firstTradeDateEpochUtc": 1674225000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "ba078ec3-1bff-3797-99d9-a2e1a25e88f8", "messageBoardId": "finmb_1793167154", "gmtOffSetMilliseconds": -14400000, "currentPrice": 0.6508, "targetHighPrice": 4.0, "targetLowPrice": 3.0, "targetMeanPrice": 3.5, "targetMedianPrice": 3.5, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 2, "totalCash": 8402500, "totalCashPerShare": 0.525, "ebitda": -7630863, "totalDebt": 21350, "quickRatio": 10.162, "currentRatio": 10.27, "debtToEquity": 0.278, "returnOnAssets": -1.0262, "returnOnEquity": -7.8059, "freeCashflow": -3916140, "operatingCashflow": -3530323, "financialCurrency": "USD", "trailingPegRatio": null}]